Marsh & McLennan Companies, Inc. (MRSH) Target Lowered by Barclays as AI Selloff Seen Overdone

Core Viewpoint - Marsh & McLennan Companies, Inc. (NYSE:MRSH) is identified as one of the most oversold stocks in the insurance sector, with analysts suggesting it presents a buying opportunity despite recent market selloffs related to AI concerns [1][2]. Group 1: Analyst Insights - Barclays has adjusted its price target for MRSH to $209 from $210 while maintaining an Overweight rating, indicating confidence in the stock despite recent selloffs [2]. - The selloff in the insurance brokerage sector is viewed as excessive by Barclays, which believes MRSH can benefit from efficiency gains and that current valuations do not fully reflect the brokerage model's durability [2][6]. Group 2: Product Development - On March 2, Marsh & McLennan launched Network Navigator, a healthcare pricing technology that allows employers to assess costs and network performance based on various criteria [3]. - This tool aims to improve network evaluation methods by providing comprehensive provider-level analytics, addressing gaps in current techniques that rely on insufficient data [4]. Group 3: Company Overview - Marsh & McLennan is a global professional services firm that offers risk management, insurance brokerage, consulting, and advisory services across various industries [4].